吉西他滨联合紫杉醇治疗晚期非小细胞肺癌的临床研究

黄志荣, 曹齐生, 杜成荣, 丁德全, 何昌霞

黄志荣, 曹齐生, 杜成荣, 丁德全, 何昌霞. 吉西他滨联合紫杉醇治疗晚期非小细胞肺癌的临床研究[J]. 实用临床医药杂志, 2012, (21): 70-72.
引用本文: 黄志荣, 曹齐生, 杜成荣, 丁德全, 何昌霞. 吉西他滨联合紫杉醇治疗晚期非小细胞肺癌的临床研究[J]. 实用临床医药杂志, 2012, (21): 70-72.
HUANG Zhirong, CAO Qisheng, DU Chengrong, DING Dequan, HE Changxia. Clinical study of gemcitabine plus paclitaxel in the treatment of advanced non-small cell lung cancer[J]. Journal of Clinical Medicine in Practice, 2012, (21): 70-72.
Citation: HUANG Zhirong, CAO Qisheng, DU Chengrong, DING Dequan, HE Changxia. Clinical study of gemcitabine plus paclitaxel in the treatment of advanced non-small cell lung cancer[J]. Journal of Clinical Medicine in Practice, 2012, (21): 70-72.

吉西他滨联合紫杉醇治疗晚期非小细胞肺癌的临床研究

基金项目: 中国高校医学期刊临床专项资金
详细信息
  • 中图分类号: R734.2

Clinical study of gemcitabine plus paclitaxel in the treatment of advanced non-small cell lung cancer

  • 摘要: 目的 探讨紫杉醇联合吉西他滨治疗晚期非小细胞肺癌(NSCLC)的近期疗效和安全性.方法 老年晚期非小细胞肺癌92例,随机分为2组:吉西他滨1000 mg联合紫杉醇120 mg方案(TG组)45例,吉西他滨联合卡铂方案(GC组)47例,每3~4周为1周期,连续用药3周期.结果 近期疗效:2组组间总有效率(RR)及疾病控制率(DCR)经比较,差异无统计学意义;TG组中位生存期为8.6个月,3年生存率约6.6%;GC组中位生存期为9个月,3年生存率约6.4%;主要不良反应是Ⅲ~Ⅳ度骨髓抑制、血液学毒性、肝功能损害等,TG组血小板减少、白细胞减少以及贫血(Ⅲ~Ⅳ度)发生率明显少于GC组.结论 吉西他滨联合紫杉醇治疗老年晚期NSCLC疗效较好,毒性反应较轻.
  • Kosmidis P A, Kalofonos H P, Christodoulou C. Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer:a phase Ⅲ study of the Hellenic Cooperative Oncology Group [J]. Annals of Oncology, 2008(1):115.
    Raez L E, Lilenbaum R. New developments in chemotherapy for advanced non-small cell lung cancer [J]. Current Opinion in Oncology, 2006(2):156.
    Rajeswaran A, Trojan A, Bumand B. Efficacy and side effects of cisplatin-and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma:a systematic review of randomized controlled trials [J]. Lung Cancer, 2008(1):1.
    赵伟庆, 季枚, 吴昌平. 培美曲塞二钠联合卡铂治疗老年中晚期非小细胞肺癌的临床研究 [J]. 中国全科医学, 2008.1140.
    Paz-Ares LG, Biesma B, Heigener D. Phase Ⅲ, Randomized, Double-Blind, Placebo Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First Line Treatment of Advanced, Nonsquamous Non-Small-Cell Lung Cancer [J]. Journal of Clinical Oncology, 2012.
    王晓云, 赵玉亮. 紫杉醇+卡铂及吉西他滨+卡铂方案治疗晚期非小细胞肺癌的临床观察 [J]. 中华医学杂志, 2010, (47):3362.doi: 10.3760/cma.j.issn.0376-2491.2010.47.014.
    蔡友鹏, 许慎, 林淑君. 紫杉醇和顺铂与紫杉醇和奈达铂治疗晚期非小细胞肺癌的对比观察 [J]. 中华肿瘤杂志, 2010(1):74.doi: 10.3760/cma.j.issn.0253-3766.2010.01.020.
    马军, 秦叔逵, 张清嫒. 中国临床肿瘤学教育专辑(2007) [M]. 哈尔滨:黑龙江科学技术出版社, 2007.186.
    Kusagaya H, Inui N, Karayama M. Biweekly combination therapy with gemcitabine and carboplatin compared with gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer:A randomized, phase-Ⅱ study [J]. Lung Cancer, 2012.
    Larsen J E, Cascone T, Gerber DE. Targeted therapies for lung cancer:clinical experience and novel agents [J]. Cancer, 2011(6):512.
计量
  • 文章访问数:  175
  • HTML全文浏览量:  28
  • PDF下载量:  7
  • 被引次数: 0
出版历程
  • 发布日期:  2013-02-27

目录

    /

    返回文章
    返回
    x 关闭 永久关闭